CLICK HERE FOR INVESTOR PORTAL
Hadean Ventures
Hadean Ventures
Hadean Ventures
  • HOME
  • TEAM
  • NEWS
  • PORTFOLIO
  • INVESTORS
  • IMPACT
  • EVENTS
  • CAREERS
  • CONTACT
    Category Archives

    News

  • All
  • Funds news
  • Portfolio news
  • Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in a Phase 1/2 Trial for T cell and B cell lymphomas

    by @hadeanventures on October 24, 2022

    Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in…

    Continue Reading
  • Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a preclinical proof-of-concept study

    by @hadeanventures on October 21, 2022

    Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a…

    Continue Reading
  • Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety

    by @hadeanventures on October 14, 2022

    The Digital Therapeutic (DTx) was developed by DTx leader Alex Therapeutics using the proprietary “Alex…

    Continue Reading
  • Cardior Announces First Patient Dosed in Phase 2 Study

    by @hadeanventures on July 27, 2022

    Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding…

    Continue Reading
  • Gesynta Pharma completes patient enrollment in its Phase II study in systemic sclerosis

    by @hadeanventures on July 15, 2022

    Stockholm, Sweden, 12 July 2022 – Gesynta Pharma AB today announces that all patients have…

    Continue Reading
  • Attgeno AB announces fully subscribed share issue to complete clinical phase II study in acute pulmonary hypertension

    by @hadeanventures on July 3, 2022

    Attgeno AB announces that a successful share issue was completed at midsummer 2022 and resulted…

    Continue Reading
  • Attgeno announces approval of initiation of Phase 2 clinical trial of Supernitro in patients with acute pulmonary hypertension

    by @hadeanventures on June 2, 2022

    Attgeno announces approval of initiation of Phase 2 clinical trial of Supernitro...

    Continue Reading
  • Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors

    by @hadeanventures on June 1, 2022

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG…

    Continue Reading
  • Gesynta Pharma’s drug candidate GS-248 granted Orphan Drug Designation by the FDA

    by @hadeanventures on April 27, 2022

    Gesynta Pharma’s drug candidate GS-248 granted Orphan Drug Designation in US by the FDA for…

    Continue Reading
  • Alex Therapeutics raises €3.5M in oversubscribed financing round

    by @hadeanventures on April 6, 2022

    Alex Therapeutics aspires to become the global go-to partner for pharma, and other life-science companies…

    Continue Reading
  • ←
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • →
  • HOME
  • TEAM
  • NEWS
  • PORTFOLIO
  • INVESTORS
  • IMPACT
  • EVENTS
  • CAREERS
  • CONTACT

What are you looking for?